News

Mon, 03/06/2019
Publication: Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.
Muenster. For the first time scientists from the University of Münster could show that multiple sclerosis (MS) alters the energy metabolism of T cells during acute phases of disease exacerbation. Therapeutic interventions targeting the metabolism of activated T cells display new potential avenues for treatment of patients with MS affecting around 250,000 people in Germany. The […]...more
Mon, 29/04/2019
Publication: Calcium influx through plasma-membrane nanoruptures drives axon degeneration in a model of multiple sclerosis.
Munich.  Here SFB researchers from Munich use in vivo calcium imaging in a multiple sclerosis model to show that cytoplasmic calcium levels determine the choice between axon loss and survival. Calcium can enter the axon through nanoscale ruptures of the axonal plasma membrane that are induced in inflammatory lesions. Neuron doi: 10.1016/ j.neuron.2018.12.023...more
Tue, 04/12/2018
SFB 128 International Symposium
SFB 128. We are happy to announce the international Symposium of the Collaborative Research Centre 128 “Multiple Sclerosis” taking place from Sunday, September 15th, till Tuesday, September 17th, 2019 in the Rhine Main region. Full details of the event will follow....more


Thu, 22/01/2015 | CRC scientists discover new protection mechanism for nerve cells after they are damaged

CRC scientists from the University Medical Center Mainz, together with colleagues from the University of Virginia, have identified a new mechanism that mediates repair of nerve cells after damage to the central nervous system. Interleukin-4, a immune system secondary messenger produced by T cells, plays a key role here. The work has been published in a recent issue of the prestigious Journal of Clinical Investigation.

You can see the authors of the paper talk about there work in the following video.

A detailed press release (in German) can also be found here.